logo
  

CACI International Q3 Profit Declines; Reiterates 2014 Guidance

CACI International Inc (CACI) reported that its third-quarter net income attributable to company decreased to $30.8 million or $1.19 per share, from $38.4 million or $1.62 per share, previuos year. Adjusted net income was $46.34 million or $1.78 per share, for the quarter.

On average, 12 analysts polled by Thomson Reuters expected the company to report profit per share of $1.22 for the quarter. Analysts' estimates typically exclude special items.

Revenue decreased to $900.4 million from $906.2 million, a year ago. Analysts expected revenue of $897.30 million for the quarter. The company said the decrease in revenue was driven primarily by delays in planned awards, lower run rates on professional services contracts, and reductions in Afghanistan-related material purchases.

The company reiterated its fiscal 2014 guidance. Revenue is expected to be in the range of $3.50 billion to $3.60 billion. Earnings per share is expected to be in the range of $5.12-$5.51. Analysts expect the company to report 2014 profit per share of $5.29 on revenue of $3.55 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT